We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sandoz, Amgen Want Federal Circuit to Review Ruling on Biosimilar Approval
Sandoz, Amgen Want Federal Circuit to Review Ruling on Biosimilar Approval
Sandoz and Amgen are separately asking the full Federal Circuit Court of Appeals to review a July decision by a three-judge panel on the biosimilar approval pathway, saying the ruling is contrary to Congress’ intent in the Biologics Price Competition and Innovation Act.